[go: up one dir, main page]

SG11201806609TA - Cancer evolution detection and diagnostic - Google Patents

Cancer evolution detection and diagnostic

Info

Publication number
SG11201806609TA
SG11201806609TA SG11201806609TA SG11201806609TA SG11201806609TA SG 11201806609T A SG11201806609T A SG 11201806609TA SG 11201806609T A SG11201806609T A SG 11201806609TA SG 11201806609T A SG11201806609T A SG 11201806609TA SG 11201806609T A SG11201806609T A SG 11201806609TA
Authority
SG
Singapore
Prior art keywords
international
pct
probability
subject
cancer
Prior art date
Application number
SG11201806609TA
Inventor
Helmy Eltoukhy
Amirali Talasaz
Original Assignee
Guardant Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guardant Health Inc filed Critical Guardant Health Inc
Publication of SG11201806609TA publication Critical patent/SG11201806609TA/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Primary Health Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 10 August 2017 (10.08.2017) WIPO I PCT (10) International Publication Number WO 2017/136603 Al 111111111111110111011111111111010111110 011101111111110011111011111111111110111111 Collect genetic profile data on a population of tumors and original tumor treatment(s) (10) W O 20 17 / 136603 Al (51) International Patent Classification: C12Q 1/68 (2006.01) GOOF 19/18 (2011.01) (21) International Application Number: PCT/US2017/016295 (22) International Filing Date: 2 February 2017 (02.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/290,375 2 February 2016 (02.02.2016) US (71) Applicant: GUARDANT HEALTH, INC. [US/US]; 505 Penobscot Drive, Redwood City, CA 94063 (US). (72) Inventors: ELTOUKHY, Helmy; 2 Barry Lane, Atherton, CA 94027 (US). TALASAZ, AmirAli; 2181 Caminio A Los Cerros, Menlo Park, CA 94025 (US). (74) Agents: STRONCEK, Jacqueline et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [Continued on next page] (54) Title: CANCER EVOLUTION DETECTION AND DIAGNOSTIC (57) : The present disclosure provides methods for determining a probability that after any of a number of therapeutic interventions, an initial state of a subject, such as somatic cell mutational status of a sub- = ject with cancer, will develop a subsequent state. Such probabilities can be used to inform a health care provider as to particular courses of treat- ment to maximize probability of a desired outcome for the subject. Identify one or more evolutionary paths of escape and evolved tumor treatment(s) (12) Based on a subject profile, predicting a probability of escape along the one or more evolutionary paths (14) FIG. 1 WO 2017/136603 Al MIDEDIMOMOIDEIR01013011100MOIMMOVOIMIE TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3))
SG11201806609TA 2016-02-02 2017-02-02 Cancer evolution detection and diagnostic SG11201806609TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290375P 2016-02-02 2016-02-02
PCT/US2017/016295 WO2017136603A1 (en) 2016-02-02 2017-02-02 Cancer evolution detection and diagnostic

Publications (1)

Publication Number Publication Date
SG11201806609TA true SG11201806609TA (en) 2018-09-27

Family

ID=59500171

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806609TA SG11201806609TA (en) 2016-02-02 2017-02-02 Cancer evolution detection and diagnostic

Country Status (7)

Country Link
US (6) US11335463B2 (en)
EP (1) EP3411505A4 (en)
JP (3) JP6987786B2 (en)
CN (2) CN116640847A (en)
CA (1) CA3013366A1 (en)
SG (1) SG11201806609TA (en)
WO (1) WO2017136603A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068153T2 (en) 2011-04-15 2024-12-28 Univ Johns Hopkins Safe sequencing system
ES2886507T5 (en) 2012-10-29 2024-11-15 Univ Johns Hopkins Pap test for ovarian and endometrial cancers
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
SG11201806609TA (en) 2016-02-02 2018-09-27 Guardant Health Inc Cancer evolution detection and diagnostic
WO2018064629A1 (en) 2016-09-30 2018-04-05 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
US10353937B2 (en) * 2017-04-17 2019-07-16 Mammoth Medical, Llc Automated characterization-vector based recommendation
SG11202001010UA (en) 2017-08-07 2020-03-30 Univ Johns Hopkins Methods and materials for assessing and treating cancer
WO2019079493A2 (en) * 2017-10-17 2019-04-25 President And Fellows Of Harvard College Methods and systems for detection of somatic structural variants
JP7304852B2 (en) * 2017-11-03 2023-07-07 ガーダント ヘルス， インコーポレイテッド Correction of sequence errors induced by deamination
EP3728642A4 (en) 2017-12-18 2021-09-15 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
CA3094717A1 (en) 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels
AU2019351130B2 (en) 2018-09-27 2025-10-23 Grail, Inc. Methylation markers and targeted methylation probe panel
CN111382756B (en) * 2018-12-28 2023-06-02 台湾中国医药大学附设医院 Imaging computer-assisted treatment response prediction system and method for rectal cancer
ES3013495T3 (en) 2019-01-31 2025-04-14 Guardant Health Inc Method for isolating and sequencing cell-free dna
DK4055187T3 (en) * 2019-11-06 2025-10-27 Univ Leland Stanford Junior METHODS FOR ANALYSIS OF NUCLEIC ACID MOLECULES
US11586964B2 (en) * 2020-01-30 2023-02-21 Dell Products L.P. Device component management using deep learning techniques
AU2021219794A1 (en) 2020-02-14 2022-09-08 The Johns Hopkins University Methods and materials for assessing nucleic acids
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US20230154618A1 (en) * 2021-11-16 2023-05-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bayesian Approach For Tumor Forecasting
CN116363647A (en) * 2023-03-29 2023-06-30 北京透彻未来科技有限公司 Lung cancer histopathological classification system based on deep semantic segmentation network

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000083A1 (en) 1999-06-29 2001-01-04 Intercet, Ltd. Human cancer virtual simulation system
US20050170528A1 (en) * 2002-10-24 2005-08-04 Mike West Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2669600A1 (en) * 2006-11-13 2008-05-29 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2008123867A1 (en) * 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CA2699376C (en) 2007-09-14 2018-10-23 University Of South Florida Gene signature for the prediction of radiation therapy response
US20090105167A1 (en) * 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
US9858392B2 (en) 2008-05-12 2018-01-02 Koninklijke Philips N.V. Medical analysis system
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
CN102858995B (en) * 2009-09-10 2016-10-26 森特瑞隆技术控股公司 Targeting sequence measurement
US9766249B2 (en) * 2010-04-19 2017-09-19 Biomarker Strategies, Llc Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
CA2806291C (en) * 2010-07-23 2023-08-29 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
JP2013532482A (en) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド Methods for quantifying prostate cancer prognosis using gene expression
WO2012024450A2 (en) * 2010-08-17 2012-02-23 Wisercare Llc Medical care treatment decision support system
WO2012079059A2 (en) * 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
EP2661505A4 (en) 2011-01-07 2015-01-14 Univ Jefferson SYSTEM AND METHOD FOR DETERMINING THE PROGNOSIS OF CANCER AND PREDICTING A RESPONSE TO THERAPY
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
EP2613278A2 (en) * 2011-12-05 2013-07-10 Koninklijke Philips Electronics N.V. Retroactive extraction of clinically relevant information from patient sequencing data for clinical decision support
EP2828218B9 (en) 2012-03-20 2021-04-07 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
GB2533006B (en) * 2012-09-04 2017-06-07 Guardant Health Inc Systems and methods to detect copy number variation
BR122021021825B1 (en) * 2012-09-20 2022-05-24 The Chinese University Of Hong Kong Method for estimating a DNA methylation level in a biological sample of an organism, and memory storage medium
US20140088989A1 (en) * 2012-09-27 2014-03-27 Balaji Krishnapuram Rapid Learning Community for Predictive Models of Medical Knowledge
HK1222684A1 (en) 2013-03-15 2017-07-07 夸登特健康公司 Systems and methods to detect rare mutations and copy number variation
EP3004394A4 (en) * 2013-06-04 2016-12-21 Univ Miami ASSAYS, METHODS AND KITS FOR ANALYZING SENSITIVITY AND RESISTANCE TO ANTICANCER DRUGS, GIVING PROGNOSTIC CANCER PATIENT, AND PERSONALIZED THERAPEUTIC STRATEGIES
WO2015183026A1 (en) * 2014-05-28 2015-12-03 주식회사 툴젠 Method for separating target dna using inactivated target-specific nuclease
US11085084B2 (en) 2014-09-12 2021-08-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acids
WO2016100638A1 (en) 2014-12-17 2016-06-23 Foundation Medicine, Inc. Computer-implemented system and method for identifying similar patients
CA3234222A1 (en) 2015-05-01 2016-11-10 Guardant Health, Inc. Diagnostic methods
WO2017062867A1 (en) 2015-10-09 2017-04-13 Helmy Eltoukhy Population based treatment recommender using cell free dna
SG11201806609TA (en) 2016-02-02 2018-09-27 Guardant Health Inc Cancer evolution detection and diagnostic

Also Published As

Publication number Publication date
US11621083B2 (en) 2023-04-04
CN109072309B (en) 2023-05-16
JP2022028907A (en) 2022-02-16
JP7805394B2 (en) 2026-01-23
EP3411505A4 (en) 2020-01-15
WO2017136603A1 (en) 2017-08-10
CN116640847A (en) 2023-08-25
JP6987786B2 (en) 2022-01-05
US11282610B2 (en) 2022-03-22
JP2019512823A (en) 2019-05-16
US20240274299A1 (en) 2024-08-15
CN109072309A (en) 2018-12-21
US20220359085A1 (en) 2022-11-10
US20190005194A1 (en) 2019-01-03
US11335463B2 (en) 2022-05-17
US20250329469A1 (en) 2025-10-23
JP7487163B2 (en) 2024-05-20
EP3411505A1 (en) 2018-12-12
US11996202B2 (en) 2024-05-28
US20230197284A1 (en) 2023-06-22
JP2024112831A (en) 2024-08-21
CA3013366A1 (en) 2017-08-10
US20210050072A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
SG11201806609TA (en) Cancer evolution detection and diagnostic
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201805157TA (en) Targeted disruption of the mhc cell receptor
SG11201808236YA (en) Method and apparatus for delivery of therapeutic agents
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201900979VA (en) Network-based automated prediction modeling
SG11201804957VA (en) Neoantigen identification, manufacture, and use
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201804836RA (en) Treatment of fibrosis
SG11201804268RA (en) Conjugates of quaternized tubulysin compounds
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof